Last reviewed · How we verify
TS-121
At a glance
| Generic name | TS-121 |
|---|---|
| Sponsor | Taisho Pharmaceutical R&D Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder (PHASE2)
- Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-121 CI brief — competitive landscape report
- TS-121 updates RSS · CI watch RSS
- Taisho Pharmaceutical R&D Inc. portfolio CI